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Abstract Most patients with acquired pure red cell aplasia
(PRCA) and some with acquired aplastic anemia (AA) re-
spond well to cyclosporine (CsA), but thereafter often show
CsA dependency. The mechanism underlying this dependen-
cy remains unknown. We established a reliable method for
measuring the regulatory T cell (Treg) count using FoxP3
and Helios expression as markers and determined the balance
between Tregs and other helper Tcell subsets in 16 PRCA and
29 AA patients. The ratios of interferon-γ-producing CD4+
(Th1) T cells to Tregs in untreated patients and CsA-
dependent patients were significantly higher (PRCA 5.77
±1.47 and 7.38±2.58; AA 6.18±2.35 and 8.94±4.06) than
in healthy volunteers (HVs; 3.33±0.90) due to the profound
decrease in the percentage of Tregs. In contrast, the ratios were
comparable to HVs in convalescent CsA-treated AA patients
(4.74±2.10) and AA patients in remission after the cessation
of CsA treatment (4.24±1.67). Low-dose CsA (100 ng/ml)
inhibited the proliferation of conventional T cells (Tconv) to a
similar degree to the inhibition by Tregs in a co-culture with a
1:1 Treg/Tconv ratio. The data suggest that CsA may reverse
the hematopoietic suppression in PRCA and AA patients by
compensating for the inadequate immune regulatory function
that occurs due to a profound decrease in the Treg count.
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Introduction
Idiopathic pure red cell aplasia (PRCA) is a refractory eryth-
ropoietic failure that is characterized by the absence of eryth-
roblasts in the bone marrow (BM) with normal white blood
cell and platelet counts. Although the exact cause is unclear,
various effector mechanisms have been proposed, including
CD8+ T cells, γδT cells, large granular lymphocytes, anti-
erythropoietin antibodies, and anti-erythropoietin receptor an-
tibodies [1–6]. Despite the various immune mechanisms that
underlie erythroid progenitor cell suppression, most PRCA
patients respond to cyclosporine (CsA), an immunosuppres-
sant which selectively suppresses T cells. Even more charac-
teristically, PRCA patients show a strong dependency on CsA:
they usually require low dose CsA to maintain good erythro-
poietic function [7]. This is in sharp contrast to the response to
CsA in patients with idiopathic aplastic anemia (AA), most of
whom can be withdrawn from CsA after achieving remission
with antithymocyte globulin (ATG) and CsA therapy [8]. The
similar dependency on CsA for hematopoietic function is ob-
served in a subset of AA patients, particularly those who pos-
sess DRB1*15:01 [9]. The reason the strong CsA dependency
on PRCA patients and this subset of AA patients remains to be
elucidated.
CD4+CD25+ regulatory T cells (Tregs) play an impor-
tant role in maintaining the homeostasis of the immune
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system by suppressing autoreactive T cell induction and
function. Tregs effectively control the development and
progression of autoimmune diseases such as type 1 diabe-
tes and psoriasis [10, 11]. Patients with immune-mediated
BM failure such as AA have been shown to have signif-
icantly reduced numbers of Tregs [12, 13]. However, it is
unclear whether the decrease in the Treg count is actively
involved in BM suppression through the failure to control
autoreactive T cells in these diseases because the BM
failure syndromes affect both myelopoiesis and
lymphopoiesis; thus, the decrease in Tregs may merely
represent T lymphocytopenia which occurs due to a de-
crease in the number of hematopoietic stem cells. The role
of Tregs in the development of immune-mediated BM
failure may become clearer by studying patients with
PRCA, in whom lymphopoiesis is not affected by causal
mechanisms which select ively inhibi t erythroid
progenitors.
To test this hypothesis, we determined the percentage and
absolute count of Tregs as well as helper T cell (Th) subsets,
including Th1, Th2, and Th17 cells, in the peripheral blood
(PB) of PRCA and AA patients, using an anti-FoxP3 antibody
(Ab) and an anti-Helios Ab. This method allows for the func-




Sixteen PRCA patients (idiopathic, n=12; thymoma-associ-
ated, n=3; and large granular lymphocytic leukemia [LGL],
n=1) and 29 AA patients (non-severe AA, n=22; and severe
AA, n=7) who were referred to our clinic from 2014 to 2015
and responded to CsA or CsA plus rabbi t ATG
(Thymoglobulin, Sanofi, Japan) therapy were included in this
retrospective analysis. Among the 16 PRCA patients, 2 were
untreated and 14 were undergoing CsA therapy after showing
a good response to CsA (n=10) or on CsA dependency (n=4)
at the time of blood sampling (Table 1). Nine of the AA pa-
tients were untreated (severe, n=3; non-severe, n=6), 5 of the
AA patients were in the convalescent phase and undergoing
CsA therapy, 6 showed CsA dependency, and 9 were remis-
sion after the cessation of CsA therapy. A total of 47 age-
matched healthy volunteers (HVs) were used as controls.
CsA dependency was defined as two or more relapses of ane-
mia (in the PRCA patients) or pancytopenia (in the AA pa-
tients) in association with a dose reduction or the cessation of
CsA, which had occurred after more than 1 year of therapy,
followed by a good response to CsA. After obtaining in-
formed consent, 10 ml of PBwas collected from these patients
and the HVs using EDTA-coated tubes. The PB was then
subjected to mononuclear cell (MC) isolation using density
gradient medium (Lymphoprep™, Norway). All of the PB
samples were analyzed within 8 h after sampling. This study
protocol (No. 287) was approved by the Ethics Committee for
Human Genome/Gene Analysis Research at Kanazawa
University Graduate School of Medical Science. Informed
consent was obtained from all individual participants included
in the study.
Cell sorting
PBMCs from HVs were stained with fluorochrome-labeled
antibodies (Abs) specific for CD4 (BD Bioscience),
CD45RA (BD Bioscience), CD25 (BD Bioscience), CD127
(eBioscience), CCR7 (R&D), and IL-1RI (R&D). After gating
on CD4+ lymphocytes, the cells were separated into the indi-
cated populations (CD4+CD45RA−CD25−CD127+ (Tconv),
CD4+CD45RA−CD25+CD127−CCR7+IL-1RI− (CCR7+IL-
1RI− Tregs), CD4+CD45RA−CD25+CD127−CCR7+IL-1RI+
(CCR7+IL-1RI+ Tregs), and CD4+CD45RA−CD25
+CD127−CCR7−IL-1RI− (CCR7−IL-1RI− Tregs)) to a high
level of purity (>97 %) by flow cytometry cell sorting with a
BD FACSAria™ Fusion Cell sorter instrument (BD
Biosciences).
The phenotypic analysis of Treg subsets
and cytokine-producing T cells
CD3+CD4+ T cells were stained with fluorochrome-labeled
Abs specific for FoxP3 (BD Bioscience), and Helios
(Biolegend) in combination with or without one of the Abs
specific to CD45RA (BD Bioscience), CD31 (eBioscience),
CCR4 (BD Bioscience), CTLA4 (BD Bioscience), and Ki67
(eBioscience). All of the intracellular staining procedures
were performed using the FoxP3 Staining Buffer Set
(eBioscience) according to the manufacturer’s instructions.
The cells were analyzed by flow cytometry (FCM; FACS
Canto II; BD Biosciences).
For the analysis of cytokine production by the Treg subsets,
stimulated PBMCs were stained with Abs specific to surface
markers, including CD3 and CD4, and then fixed/
permeabil ized with a FoxP3 Staining Buffer Set
(eBioscience), and stained with Abs specific to intracellular
proteins, including Helios, FoxP3, IL-2 (BD Bioscience), IL-
17, and INF-γ.
For the measurement of the different Th subsets, PBMCs
were stimulated by phorbol myristate acetate (PMA; 50 ng/ml,
Sigma-Aldrich) and ionomycin (1 μg/ml, Sigma-Aldrich) in
the presence of Golgi Stop (0.75 μl/ml, BD Bioscience) in a
tissue culture incubator for 4 h, and the cells were then washed
and stained with fluorescence-labeled anti-CD3 and anti-CD4
Abs and analyzed by FCM to determine the percentage of
CD3+CD4+ T cells that were positive for cytoplasmic
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INF-γ+ (Th1, BD Bioscience), IL-4+ (Th2, eBioscience), and
IL-17+ (Th17, eBioscience) cells [14].
The assessment of the proliferation and suppressive
function of Tregs
Ex vivo-sorted CD4+ T cell populations were labeled with
carboxyfluorescein succinimidyl ester (CFSE; 2.5 μM;
Invitrogen), stimulated with Dynabeads® Human T-
Activator CD3/CD28 (Life Technology) at a cell/bead ratio
of 4:1, as described previously [14]. The cells were cultured
for 4 days in the presence of 200 IU of IL-2 (Promega) in
OpTmizer™ CTS™ T-Cell Expansion medium (Life
Technology). To assess the inhibitory function of Tregs,
2 × 104 Tregs were cultured with different ratios of CFSE-
labeled conventional T cells (Tconvs). The cells were collect-
ed at day 4, and the CFSE dilution was assessed by FCM.
The assessment of Tconv proliferation in the presence
of CsA
Tconvs were sorted by FACS Aria Fusion and labeled with
CFSE. A total of 1×105 cells were cultured in the presence of
anti-CD3/CD28 Ab beads with a cell/bead ratio of 4:1 in
OpTmizer™CTS™ T-Cell Expansionmedium supplemented
with 200 IU/ml of IL-2 with different doses of CsA. The cells
were collected on day 4, and the CFSE dilution was assessed
by FCM.
Statistical analysis
Statistical comparisons of the various lymphocyte subsets
were performed using a paired t test or the Mann-Whitney U
test. The GraphPad Prism software program (version 5 for
Windows, San Diego, CA, USA) was used for the statistical
analyses.
Results
The definition of the Treg subsets by flow cytometry
with anti-Helios and anti-FoxP3 antibodies
First, we determined the phenotypes of the Treg subsets of
HVs (defined by Helios expression) to validate the use of this
antigen as a Treg marker. Although the expression of FoxP3
by CD4+ T cells decreased in a time-dependent manner after
sampling, it was stable within 8 h (data not shown). For this
reason, the analyses were performed within 8 h after the sam-
pling of fresh PBMCs. CD4+FoxP3+Helios+ T cells (Helios+
Tregs) and CD4+FoxP3+Helios− T cells (Helios− Tregs)
accounted for 6.5±1.6 and 2.0±0.6 % of the CD4+ T cells
of HVs (Fig. 1a). Helios− Tregs produced higher amounts of
IL-2, IL-17, and IFN-γ than Helios+ Tregs (Fig. 1b). This
finding was consistent with previous reports [14–17]. Both
subsets highly expressed CTLA4, CCR4 and contained ap-
proximately 12 % Ki67+ cells, indicating that the two T cell
subsets were activated in vivo (Fig. S1). The proportion of
Table 1 Characteristics of PRCA patients




WBC (×109/l) Hb (g/l) Lym (×109/l) CD4 (×109/l)
1 69 F Idiopathic 60 In convalescence 3.850 108 0.8 0.14
2 59 F Idiopathic 100 CsA dependent 4.280 119 1.4 0.30
3 81 M Thymoma associated 100 In convalescence 5.600 113 2.1 0.75
4 81 F LGL leukemia 100 In convalescence 25.000 64 1.4 0.09
5 59 M Idiopathic 160 In convalescence 3.500 130 2.3 0.51
6 78 M Idiopathic 160 In convalescence 4.480 100 2.3 0.47
7 57 M Idiopathic 220 In convalescence 2.780 107 0.8 0.34
8 85 F Idiopathic 80 CsA dependent 4.600 119 1.2 0.59
9 72 F Idiopathic 180 In convalescence 3.500 91 1.8 0.50
10 85 F Idiopathic 80 In convalescence 3.940 81 2.0 0.35
11 45 M Idiopathic 120 In convalescence 3.300 111 1.7 0.68
12 90 F Idiopathic 150 In convalescence 6.300 80 1.2 0.61
13 81 M Thymoma associated 140 CsA dependent 3070 115 2.2 0.43
14 40 F Idiopathic 120 CsA dependent 2.950 106 1.0 0.20
15 83 F Thymoma associated – Untreated 4.600 62 1.8 0.35
16 66 F Idiopathic – Untreated 3.500 65 2.1 0.70
CsA cyclosporine A, F female, M male, WBC white blood cell, Hb hemoglobin, Lym lymphocyte, LGL large granular lymphocyte
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CD31 cells that had recently migrated from the thymus was
higher in the Helios+ Tregs than in the Helios− Tregs (Fig. S1).
To functionally characterize CD4+FoxP3+Helios+ T cells,
we sorted CD4+CD45RA−CD25+CD127−CCR7−IL-1RI−
( C C R 7 − I L - 1 R I − T r e g ) a n d C D 4 + C D 4 5 R A
−CD25+CD127−CCR7+IL-1RI+ (CCR7+IL-1RI+ Treg) frac-
tions that were compatible with Helios+ Tregs and Helios−
Tregs, respectively (Fig. 2a), and tested their effects on the
proliferation of T cells stimulated by anti-CD3/CD28 Ab
beads. CCR7−IL-1RI− Tregs showed more divisions than
CCR7+IL-1RI+ Tregs after 4 days of in vitro culture
(Fig. 2b). CCR7−IL-1RI− Tregs were a more potent inhibitor
of autologous Tconv proliferation than CCR7+IL-1RI+ Tregs
(Fig. 2c, d).
A decreased percentage and absolute Treg count in PRCA
and AA patients
The percentage and absolute counts of Helios+ Tregs in PRCA
patients were significantly lower than those in HVs including
two untreated PRCA patients (3.5± 0.2 vs 6.5± 1.6 % and
0.0179 ± 0.0075 × 109 vs 0 .0531 ± 0.0211 × 109 / l ,
respectively), 10 convalescent PRCA patients who were un-
dergoing CsA treatment (3.9±1.6 vs 6.5±1.6 %, P<0.0001
and 0.0161 ± 0.0070 × 109 vs 0.0531 ± 0.0211 × 109/l,
P< 0.0001), and four CsA-dependent PRCA patients (4.1
± 1.9 vs 6.5 ± 1.6 %, P= 0.0261 and 0.0158± 0.0102× 109
vs 0.0531 ± 0.0211 × 109/l, P = 0.0021, Fig. 3a, b and
Table S1). A similar decrease in the percentage of Tregs was
observed in the untreated AA patients and the CsA-dependent
AA patients, but not in the convalescent AA patients who
were undergoing CsA treatment or in the AA patients who
were in remission after the cessation of CsA treatment. Of
note, the Helios+ Treg percentages of the CsA-treated conva-
lescent PRCA patients were significantly lower than those of
the CsA-treated convalescent AA patients (3.9± 1.6 vs 5.7
±0.9 %, P=0.0370) (Fig. 3b). With the exception of the con-
valescent PRCA patients, who had a significantly lower per-
centage of Helios− Tregs than the HVs, the percentages of
Helios− Tregs were similar among the PRCA and AA patients
and the HVs (Fig. S2). The absolute Helios− Treg counts in the
convalescent PRCA patients, the CsA-dependent PRCA pa-
tients, and the CsA-dependent AA patients were also signifi-
cantly lower than the counts in the HVs (Fig. S2). The
Fig. 1 The phenotypic
differences between Helios+
Tregs and Helios− Tregs. The
percentages of Helios+ and
Helios− Tregs in the CD4+ T cells
of 47 healthy volunteers (HVs)
with a representative flow
cytometry scattergram which was
used to determine each of the
subset percentages (a). The
percentages of IL-2, IL- 17 and
IFN-γ secreting cells in Helios+
and Helios− Tregs with a
representative scattergram from
6 HVs (b). *, P < 0.05; **,
P < 0.01; ***, P < 0.001
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percentages of Ki67-positive cells in Helios+ Tregs were sim-
ilar among the PRCA patients (untreated, 13.4±7.4 %; con-
valescent, 13.4± 6.3 %; CsA dependent, 11.8± 4.3 %), the
AA patients who were in remission (13.8±2.9 %), and the
HVs (12.5±2.7 %) while the Ki67-positive cell percentages
in the untreated AA (7.4±1.5 %, P=0.0022) and in the CsA-
dependent AA (8.6±0.6 %, P=0.0238) patients were signif-
icantly lower than the percentages in the HVs (Fig. 3c).
When three different CD4+FoxP3+ T cell subsets (defined
by the expression levels of CD45RA and FoxP3) were ana-
lyzed, the percentages of CD45RA+FoxP3low resting Tregs
and CD45RA+FoxP3high activated Tregs in all of the three
subsets of PRCA patients tended to be lower than those in
HVs while the percentages of CD45RA−FoxP3low cytokine-
producing non-Tregs in the three subsets were higher than
those of HVs (Fig. 3e). Representative scattergrams of an
Fig. 2 The suppression function
of Helios+ Tregs and Helios−
Tregs. The gating strategy and the
expression of FoxP3 and Helios
in four different Tcell populations
after sorting (>97 % purity):
conventional T cells (Tconv),
CCR7+IL-1RI− Tregs, CCR7+IL-
1RI+ Tregs, and CCR7−IL-1RI−
Tregs (a). The proliferation of
CFSE-labeled CCR7+IL-1RI+
Tregs and CCR7−IL-1RI− Tregs
was analyzed by FCM after
4 days of culture (b). The
proliferation of CFSE-labeled
Tconvs is shown after co-culture
with CCR7+IL-1RI+ Tregs or
CCR7−IL-1RI− Tregs (c). The
inhibitory function of CCR7+IL-
1RI+ Tregs and CCR7−IL-1RI−
Tregs was analyzed after 4 days of
co-culture. Data were collected
from three separate experiments
(d)
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HV, a PRCA patient, and an AA patient are shown in Fig. 3d
[18]. Among the AA patients, the activated Treg percentages
of the untreated AA patients, the convalescent AA patients,
and the CsA-dependent AA patients were significantly lower
than those in HVs while the AA patients who were in remis-
sion had a similar percentage of activated Tregs (25.3±8.6 %)
to HVs (23.9±7.4 %). The percentages of cytokine-producing
non-Tregs in untreated AA patients, CsA-dependent AA pa-
tients, and AA patients who were in remission were signifi-
cantly higher than in HVs (Fig. 3e).
The T helper cell subsets in PRCA and AA patients
The ratios of CD4+ T cells to CD8+ T cells were significantly
lower in PRCA patients than in HVs (Fig. S3a). In PRCA
patients, the CD4+ T cell counts of convalescent and CsA-
dependent patients were significantly lower than in HVs
(Fig. S3b). In AA patients, the CD4+ T cell counts in CsA-
dependent AA patients and AA patients who were in remis-
sion were significantly lower than in HVs, while those of
untreated AA and convalescent AA patients were comparable
to HVs (Fig. S3b).
In contrast to the decreased percentages of Tregs, the per-
centages of Th1, Th2, and Th17 cells in all of the PRCA
subsets were comparable to those in HVs (Fig. S4a, b). In
AA patients, the percentages of Th1 and Th2 cells in the four
different groups were also comparable to HVs, while the per-
centages of Th17 cells in untreated AA (3.1 ± 2.0 %,
P = 0.0422) and CsA-dependent AA (2.9 ± 1.6 %,
P=0.0392) patients were significantly higher than in HVs
(1.6 ± 0.7 %), (Fig. S4a, b). The absolute counts of Th1,
Th2, and Th17 cells were significantly lower than in HVs
due to the decreased CD4+ T cell counts in PRCA patients
(Fig. S3c). In contrast, the untreated AA patients showed a
significant increase in their Th1 and Th17 cell counts in com-
parison to HVs while the Th1 and Th17 cell counts in other
AA patients were comparable or lower than those in HVs due
to their decreased CD4+ T cell counts (Fig. S4b).
The ratios of each Th subset to Tregs
As a result of the decrease in the percentage of Tregs, the Th1/
Treg and Th2/Treg ratios of the CsA-dependent PRCA pa-
tients (7.38±2.58, P=0.0145 and 1.27± 0.37, P= 0.0414)
and the Th1/Treg ratio of convalescent CsA-treated PRCA
patients (7.49 ±4.64, P= 0.0004) were significantly higher
than those of HVs (3.33 ± 0.90, 0.83 ± 0.24) (Fig. 3f and
Table S1). The Th1/Treg, Th2/Treg, and Th17/Treg ratios of
untreated PRCA patients tended to be higher than those of
HVs. Similarly, untreated AA patients had significantly in-
creased Th1/Treg (6.18±2.35, P=0.0007), Th2/Treg (1.36
±0.72, P=0.0214), and Th17/Treg (0.69±0.33, P=0.0008)
ratios and CsA-dependent AA patients had significantly
increased Th1/Treg (8.94±4.06, P=0.0014) and Th17/Treg
(0.81±0.33, P=0.0005) ratios in comparison to HVs. In con-
trast to untreated AA and CsA-dependent AA patients, con-
valescent CsA-treated AA patients and AA patients who were
remission had similar Th1/Treg, Th2/Treg, and Th17/Treg
ratios to HVs (Fig. 3f).
The effect of CsA on Tconv proliferation
The normal blood cell counts and lower Treg counts of CsA-
treated PRCA patients who were in remission and CsA-
dependent AA patients may indicate that, in the blood, CsA
complements the inadequate suppression of the Tconv func-
tion by Tregs due to their decreased number. We therefore
tested the effect of CsA on the proliferation of Tconvs using
a CFSE assay. As shown in Fig. 4, CsA inhibited Tconv pro-
liferation in a dose-dependent manner. CsA at concentrations
of 50 and 100 ng/ml, which can be achieved in blood by the
administration of 2–3 mg/kg of CsA, inhibited the prolifera-
tion of Tconvs by 25.9 and 50.4 %, respectively (Fig. 4a, b).
Discussion
Several studies have focused on the role of Tregs in the path-
ophysiology autoimmune diseases such as AA, type 1
Fig. 3 The imbalance of the Helios+ Treg and T helper subsets in the
PRCA and AA patients. The expression of FoxP3 and Helios in 47 HVs,
16 PRCA patients, and 29 untreated AA patients (UT untreated, Conval
convalescent, CsA-D CsA-dependent, Rem in remission) with
representative scattergrams (a). Percentages and the absolute counts of
Helios+ Tregs in 16 PRCA patients (UT, n= 2; Conval, n= 10; CsA-D,
n= 4), 29 AA patients (UT, n= 9; Conval, n = 5; CsA-D, n = 6; and Rem,
n= 9), and 47 HVs were analyzed (b). The Ki67 expression levels on
Helios+ Tregs in 12 PRCA patients (UT, n= 2; Conval, n= 6; CsA-D,
n= 4), 15 AA patients (UT, n= 6; CsA-D, n= 3; Rem, n= 6), and 6 HVs
are shown (c). Representative scattergrams showing the expression of
CD45RA and FoxP3 in an HV, a PRCA patient, and an AA patient
(rTreg resting Treg, aTreg activated Treg, cTreg cytokine-producing
non-Treg) (d). The percentage of rTregs (CD45RA+FoxP3low), aTregs
(CD45RA−FoxP3high), and cTregs (CD45RA−FoxP3low) in the total
FoxP3+CD4+ T cells of 30 HVs (25.5 ± 10.0, 23.9 ± 7.4, and 50.5
± 7.5 %), 16 PRCA patients (UT, n= 2 [4.6 ± 3.3, 20.5 ± 19.2, and 74.8
± 15.8 %]; Conval, n = 10 [17.4 ± 9.9 %, P= 0.0091; 15.1 ± 9.3 %,
P= 0.0063, and 67.5 ± 7.6 %, P< 0.0001]; and CsA-D, n = 4 [10.6
± 7.8 %, P= 0.0129; 13.3 ± 10.2 %, P= 0.0511, and 76.1 ± 17.3 %,
P = 0.0081]), and 29 AA patients (UT, n = 9 [15.5 ± 11.2 %,
P= 0.0224; 13.5 ± 7.3 %, P= 0.0012, and 71.0 ± 12.8 %, P< 0.0001];
Conval, n= 5 [30.4 ± 11.4 %, P= 0.3339; 15.0 ± 6.5 %, P= 0.0320, and
54.6 ± 11.7 %, P= 0.2679]; CsA-D, n = 6 [20.1 ± 12.6, P= 0.5666; 12.5
± 3.4 %, P= 0.0009, and 67.4 ± 10.9 %, P= 0.0014]; and Rem, n = 9
[10.4 ± 5.9 %, P= 0.0002; 25.3 ± 8.6 %, P= 0.7769, and 64.3 ± 9.0 %,
P= 0.0008]) were analyzed by FCM. Each of the Treg subsets in PRCA
and AA patients was compared to a similar subset of HVs (e). The ratios
of Th1/Treg, Th2/Treg, and Th17/Treg in 16 PRCA patients (UT, n= 2;
Conval, n = 10; and CsA-D, n= 4) and 26AA patients (UT, n = 9; Conval,
n= 5; CsA-D, n= 6; and Rem, n = 6) were compared to those of 32 HVs.
The ratios are shown (f). *P< 0.05; **P< 0.01; ***P< 0.001
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d i a b e t e s , a n d p s o r i a s i s a n d h av e f o u nd t h a t
CD4+CD25+FoxP3+ Treg numbers were profoundly de-
creased in patients with active disease [19–23]. Previous stud-
ies on bone marrow failure syndromes revealed a decrease in
the CD4+CD25+FoxP3+ Treg number, an impaired suppres-
sive function of Tregs on Tconvs, and the reduced trafficking
of Tregs to the BM in patients with AA [12, 13]. However, it
remains unclear which phenotype best represents functional
T r e g s i n h uman s . We d e f i n e d Tr e g c e l l s a s
CD4+FoxP3+Helios+ T cells because Helios, a member of
the Ikaros gene family, is expressed by 70–80 % of human
FoxP3+ T cells and is known to be a good marker for natural
Tregs [24, 25]. When we determined the phenotype of the
CD4+ T cells of HVs and PRCA patients using anti-
CD45RA and an t i - FoxP3 Abs , we found t h a t
CD45RA−FoxP3low cells (cytokine-producing non-Tregs)
accounted for 50.5± 7.5 % of FoxP3+ cells in HVs, 67.5–
76.1 % in PRCA patients, and 54.6–67.4 % in AA patients;
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however, the border between CD45RA−FoxP3high cells and
CD45RA−FoxP3low cells was sometimes unclear in patients
with PRCA and AA due to their decreased Treg percentages
(Fig. 3d).Moreover, not all cytokine-producing non-Treg cells
are reported to be cytokine-producing cells [16, 18]. In con-
trast, anti-Helios mAbs clearly divided FoxP3+ cells into
Helios+ and Helios− subpopulations (Fig. 1a), and Helios+
Treg cells rarely produced many cytokines in comparison to
Helios− Treg cells (Fig. 1b). Our co-culture experiments using
sorted CCR7+IL-1R1+ Tregs and CCR7−IL-1R1− Tregs,
which are compatible with Helios− and Helios+ Tregs, respec-
tively, showed that the Helios+ Tregs exerted greater inhibito-
ry effects on the proliferation of Tconvs than Helios− Tregs.
These results were in agreement with a previous study which
found that the Helios− Treg subpopulation harbors a larger
population of non-suppressive clones than the Helios+ cell
subset [17]. These results validated the use of a phenotype
Helios+ as a marker of functional Tregs.
Our study revealed, for the first time, a significant de-
crease in the percentage and in the absolute count of
Helios+ Tregs in PRCA patients regardless of CsA treat-
ment status. Unlike AA patients, lymphopoiesis is not
affected by a decrease in the number of hematopoietic
stem cells in PRCA patients where only the erythroid
precursors are diminished. Our results therefore substan-
tiated that a decrease in the Treg percentage and/or an
increase in the Th/Treg ratio contributes to failed hemato-
poiesis. One may argue that in CsA-treated PRCA pa-
tients who are in remission, the marked decrease in
Tregs may be caused by the long-term administration of
CsA. Several studies have shown the suppressive effects
of CsA on Treg numbers [26, 27]. However, in patients
with atopic dermatitis, low-dose CsA treatment (2 mg/kg/
day) results in an increase in the number of peripheral
Tregs without affecting the CD3+, CD4+, and CD8+ cell
populations [28, 29]. Similarly, a lower dose of CsA has
been shown to promote Treg development in a rat cardiac
allograft model [30]. A recent study also showed that
clinically relevant CsA concentrations increased Treg
numbers in vitro [31]. Moreover, a decrease in the
Helios+ Treg percentage was also observed in PRCA
and AA patients before CsA therapy, and the normal
Treg percentage was maintained in convalescent CsA-
treated AA patients. These findings suggest that a de-
creased in Treg count is related to the disease activity of
immune-mediated bone marrow failure.
A striking difference in the response of PRCA and AA
patients to CsAwas the extent of Treg recovery in association
with hematologic recovery. Unlike convalescent CsA-treated
AA patients, the Treg percentage and the Th1/Treg ratio
remained abnormal in the PRCA patients who responded to
CsA. These findings are compatible with the CsA dependency
that most PRCA patients show in the clinical setting. A pre-
vious study on the helper T cell subsets of PRCA patients
demonstrated an increase in the number of Th2 cells in the
active phase and the elevation of theTh1/Th2 ratio concomi-
tant with hematological improvement [32]. Our study re-
vealed no significant differences in the percentages of Th1,
Th2, and Th17 cells between the PRCA patients and the HVs;
however, the absolute counts of Th1, Th2, and Th17 cells
were lower in the PRCA patients than in the HVs due to their
low CD4 cell count. The apparent decrease in Tregs resulted
in a significant increase in the Th1/Treg in convalescent and
CsA-dependent PRCA patients. An imbalance between Ths
and Tregs has been implicated in the disease activity of several
autoimmune diseases, including rheumatoid arthritis, SLE,
Fig. 4 The effect of CsA on
conventional T cell proliferation.
The expression of CFSE in
Tconvs after treatment with
different doses of CsA (a). The
inhibitory effects of CsA on
Tconvs are shown (b); one
representative result from three
different experiments is shown
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and multiple sclerosis [33–36]. Consistent with previous stud-
ies on AA using different Treg markers [12, 20], the Th1/Treg,
Th2/Treg, and Th17/Treg ratios were markedly higher in our
patients with active AA than in HVs. These findings suggest
that increased Th1/Treg ratios are correlated with the disease
activity of PRCA and AA.
Despite the heterogeneity of its pathogenesis, most PRCA
patients respond to monotherapy with CsA [7, 37, 38]. The
reason for the uniform response to CsA and the target of CsA
remain unknown. The results of the present study suggest that
the decreased Treg count is an abnormality that is common to
PRCA patients and that CsA may complement the role of
Tregs in vivo. This hypothesis was substantiated by our
in vitro findings: 50–100 ng/ml of CsA effectively inhibited
proliferation of Tconv, to a similar degree to the suppression
by Tregs to Tconv at ratios of 1/3 and 1/1 of Tregs (Figs. 2d
and 4b). Blood trough levels of CsA ranging 50–100 ng/ml
can be achieved by the administration of 2–3 mg/kg of CsA
[28]. A recent study by Philippe et al. demonstrated that an
optimal CsA trough blood concentration for the treatment of
SAAwas 100 ng/ml [39].
In the management of PRCA and AA patients who respond
to IST, physicians often have difficulties in determining when
the CsA dose should be tapered off. The persistently high Th1/
Treg ratio of convalescent PRCA patients and the high Th1/
Treg ratios detected in patients with CsA-dependent PRCA or
AA may indicate that the patients have not acquired tolerance
to the autoimmune attack against hematopoietic cells and that
CsA treatment, which potentially complements the role of
Tregs, should be continued.
In summary, the current study demonstrated a profound
decrease in Helios+ Tregs and an increased Th1/Treg ratio in
PRCA and AA patients who were responsive to CsA. The
decrease in the Treg percentage is a potential therapeutic target
in PRCA. Clinical trials of cytokines that are known to aug-
ment Treg function [40–43] are warranted as a curative treat-
ment in patients with immune-mediated BM failure who are
responsive to CsA.
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